Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170950-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
| Ab170950-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $297.90 | |
| Ab170950-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $777.90 | |
| Ab170950-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,227.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Rilotumumab (anti-HGF) - Primary antibody, specific to HGF, >95%, high purity, Human IgG2SA |
|---|---|
| Synonyms | DFNB39 antibody; F TCF antibody; Fibroblast derived tumor cytotoxic factor antibody; Hepatocyte growth factor (hepapoietin A; scatter factor) antibody; Hepatocyte growth factor antibody; Hepatocyte growth factor beta chain antibody; Hepatocyte growth fac |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | HGF |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Hepatocyte growth factor inhibitor |
| Product Description | Rilotumumab (anti-HGF) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab (anti-HGF) shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. |
| Isotype | Human IgG2SA |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145.2 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 872514-65-3 |
Rilotumumab (anti-HGF) (Ab170950) - ELISA
Immobilized Recombinant human HGF protein (rp156180) at 1.0 μg/mL can bind Rilotumumab (anti-HGF) (Ab170950) with the EC₅₀ of 21.92 ng/mL.
Rilotumumab (anti-HGF) (Ab170950) - SEC
The purity of Rilotumumab (anti-HGF) (Ab170950) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001513 | Certificate of Analysis | Nov 02, 2023 | Ab170950 |
| ZJ23F1001514 | Certificate of Analysis | Nov 02, 2023 | Ab170950 |
| 1. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.. (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors.. J Med Chem, 51 (18): (5766-5779). [PMID:18763753] |
| 2. Liang Z, Ai J, Ding X, Peng X, Zhang D, Zhang R, Wang Y, Liu F, Zheng M, Jiang H, Liu H, Geng M, Luo C.. (2013) Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.. ACS Med Chem Lett, 4 (4): (408-413). [PMID:24900685] |
| 3. Hartmann, G G and 6 more authors.. (1992) A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.. Proceedings of the National Academy of Sciences of the United States of America, (1): [PMID:1280830] |
| 4. Lokker, N A NA and 6 more authors.. (1992) Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.. The EMBO journal, [PMID:1321034] |
| 5. Shimizu, N N and 7 more authors.. (1992) Hepatocyte growth factor is linked by O-glycosylated oligosaccharide on the alpha chain.. Biochemical and biophysical research communications, (30): [PMID:1482348] |
| 6. Chan, A M AM and 5 more authors.. (1991) Identification of a competitive HGF antagonist encoded by an alternative transcript.. Science (New York, N.Y.), (29): [PMID:1720571] |
| 7. Rubin, J S JS and 9 more authors.. (1991) A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.. Proceedings of the National Academy of Sciences of the United States of America, (15): [PMID:1824873] |
| 8. Miyazawa, K K, Kitamura, A A, Naka, D D and Kitamura, N N.. (1991) An alternatively processed mRNA generated from human hepatocyte growth factor gene.. European journal of biochemistry, (10): [PMID:1826653] |
| 9. Weidner, K M KM and 9 more authors.. (1991) Evidence for the identity of human scatter factor and human hepatocyte growth factor.. Proceedings of the National Academy of Sciences of the United States of America, (15): [PMID:1831266] |
| 10. Seki, T T, Hagiya, M M, Shimonishi, M M, Nakamura, T T and Shimizu, S S.. (1991) Organization of the human hepatocyte growth factor-encoding gene.. Gene, (30): [PMID:1831432] |
| 11. Miyazawa, K K, Kitamura, A A and Kitamura, N N.. (1991) Structural organization and the transcription initiation site of the human hepatocyte growth factor gene.. Biochemistry, (24): [PMID:1832556] |
| 12. Seki, T T and 8 more authors.. (1990) Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte.. Biochemical and biophysical research communications, (15): [PMID:2145836] |
| 13. Miyazawa, K K and 9 more authors.. (1989) Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor.. Biochemical and biophysical research communications, (15): [PMID:2528952] |
| 14. Nakamura, T T and 7 more authors.. (1989) Molecular cloning and expression of human hepatocyte growth factor.. Nature, (23): [PMID:2531289] |
| 15. Cioce, V V and 7 more authors.. (1996) Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity.. The Journal of biological chemistry, (31): [PMID:8662798] |
| 16. Zhou, H H and 7 more authors.. (1998) The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site.. Structure (London, England : 1993), (15): [PMID:9493272] |
| 17. Ultsch, M M, Lokker, N A NA, Godowski, P J PJ and de Vos, A M AM.. (1998) Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution.. Structure (London, England : 1993), (15): [PMID:9817840] |
| 18. Schultz, Julie M JM and 22 more authors.. (2009) Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.. American journal of human genetics, [PMID:19576567] |
| 19. Tolbert, W David WD, Daugherty-Holtrop, Jennifer J, Gherardi, Ermanno E, Vande Woude, George G and Xu, H Eric HE.. (2010) Structural basis for agonism and antagonism of hepatocyte growth factor.. Proceedings of the National Academy of Sciences of the United States of America, (27): [PMID:20624990] |
| 20. Tanaka, Kaoru K and 14 more authors.. (2012) SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer.. PloS one, [PMID:22242148] |
| 21. Yoshiyama, Y Y and 9 more authors.. (1991) Identification of the N-terminal residue of the heavy chain of both native and recombinant human hepatocyte growth factor.. Biochemical and biophysical research communications, (15): [PMID:1826837] |
